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Abstract
Objectives. We conducted a systematic review and meta-analysis to determine the magnitude of infection
risk in patients with SLE and evaluate the effect of general and SLE-related factors on infection risk.
Methods. We searched MEDLINE and Embase from inception to July 2018, screening for observational
studies that evaluated infection risk in patients with SLE compared with the general population/healthy
controls. Outcomes of interest included overall severe infection, herpes zoster infection/reactivation,
opportunistic infections, pneumonia and tuberculosis. Random-effects models were used to calculate
pooled risk ratios (RRs) for each type of infection. Sensitivity analysis assessed the impact of removing
studies with high risk of bias.
Results. Eleven retrospective or prospective cohort studies were included in the meta-analysis: overall se-
vere infection (n¼ 4), pneumonia (n¼ 6), tuberculosis (n¼ 3) and herpes zoster (n¼ 2). Pooled RRs for overall
severe infection significantly increased for patients with SLE compared with the general population/healthy
controls [RR 2.96 (95% CI 1.28, 6.83)]. Pooled RRs for pneumonia, herpes zoster and tuberculosis showed
significantly increased risk compared with the general population/healthy controls [RR 2.58 (1.80, 3.70), 2.50
(2.36, 2.65) and 6.11 (3.61, 10.33), respectively]. Heterogeneity and evidence of publication bias were pre-
sent for all analyses, except herpes zoster. Sensitivity analyses confirmed robustness of the results.
Conclusion. Patients with SLE have significantly higher risk of infection compared with the general popula-
tion/healthy controls. Efforts to strengthen strategies aimed at preventing infections in SLE are needed.
Protocol registration. PROSPERO number: CRD42018109425.
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Rheumatology key messages
. Rates of infections are higher among persons with SLE compared with the general population.
. Pooled risk for overall severe infections is 3.0-fold, tuberculosis 6.1-fold, pneumonia 2.6-fold
and herpes zoster 2.5-fold.
. SLE patients have significantly higher risk of infection compared with the general population/healthy controls.
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Introduction
SLE is a chronic autoimmune disease that affects mul-
tiple organ systems, leading to a variety of clinical mani-
festations [1]. Increased disease activity, characterized
by recurrent and unpredictable flares, can occur in
patients with SLE and may be associated with organ
damage and increased mortality [2]. SLE is associated
with increased comorbidities [3], which may result from
disease activity and CS use [4].
Infections are the leading cause of morbidity and mor-
tality in patients with SLE [5, 6]. Approximately half of
patients with SLE experience a severe infection during
the course of their disease, and 11–23% of hospitaliza-
tions among patients with SLE are due to infections [6–
8]. One-third of SLE-related deaths are attributable to an
infectious organism [5, 9]. Bacterial infections are the
most common aetiological agent in SLE. In a large regis-
try study (The Registry of Systemic Lupus
Erythematosus Patients of the Spanish Society of
Rheumatology), bacterial infections accounted for
51.9% of all infections, followed by viruses (11.9%) and
fungi (2.3%) [10]. In the same study, the most frequent
infection sites were the respiratory tract (35.5%), urinary
tract (15.0%) and soft tissues (13.3%) [10, 11].
Although many bacterial infections are more prevalent
in patients with SLE than in healthy people, the causal
organisms do not vary from the general population and
include pathogens such as Staphylococcus aureus,
Streptococcus pneumonia and Escherichia coli [12]. SLE
disease activity, increased CS use and SLE-associated
immunological abnormalities have all been associated
with increased infections in patients with SLE [13].
Opportunistic infections are also underreported in
patients with SLE due to their mimicry of active lupus
[14].
Some studies have assessed risk of infection in
patients with SLE; however, to date, no meta-analyses
have been performed to provide a comprehensive over-
view of infection risk. We aimed to conduct a systematic
review and meta-analysis to examine the magnitude of
risk of opportunistic infections, tuberculosis and herpes
zoster, as well as hospitalization rates due to infections.
We also aimed to explore the impact of demographic
factors (age and sex), SLE-related factors (treatment




This study was conducted in accordance with the Meta-
analysis Of Observational Studies in Epidemiology and
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses guidelines for conducting and
reporting systematic reviews [15, 16]. The study protocol
is published via PROSPERO: International prospective
register of systematic reviews (#CRD42018109425) [17].
We searched for full-text reports containing original data
in MEDLINE and Embase, and in reference lists of
included articles. The detailed search strategy is avail-
able in supplementary Table S1, available at
Rheumatology online.
Eligibility criteria
We included full publications of observational studies
(cohort, cross-sectional and case–control studies and
analysis of hospital records/database) that evaluated
risk of infection events in adult patients with an SLE
diagnosis identified by International Classification of
Diseases (ICD-7, ICD-8, ICD-9 or ICD-10) codes or ACR
criteria [18, 19] compared with the general population
(all individuals without reference to any specific charac-
teristic) or healthy controls (patients without SLE or
other autoimmune conditions). Outcomes reported in
this manuscript include fatal (leading to death) and non-
fatal (not leading to death) infection events for overall
severe infection, pneumonia, herpes zoster, tubercu-
losis, bacteraemia and sepsis. Studies were included if
they assessed risk using either hazard ratios, rate ratios,
risk ratios (RRs), odds ratios, incidence rate ratios, pro-
portionate morbidity ratios, standardized mortality rate
or standardized incidence rate, with 95% CIs. Abstracts
of unpublished studies were excluded as data were not
reported in a form that could be used for formal
comparison.
Screening and abstraction process
Two reviewers independently performed two-stage
screening (title/abstract and full-text screening), data ex-
traction and risk of bias assessment (N.P. and L.N.); dis-
agreement was resolved by consensus involving a third
reviewer (J.L.). Studies that met eligibility criteria and
reported original data were included in the review. Data
on study characteristics and the effect measure for out-
comes of interest (fatal and non-fatal events) were
extracted.
Risk of bias and quality assessment
Risk of bias for observational studies was assessed by
an SLE-specific 12-point scale and the Newcastle-
Ottawa scale [20].
The SLE-specific 12-point scale was used in previous
SLE systematic reviews [21–27]. Each study was scored
according to five domains: (i) source of the study sam-
ple, (ii) cohort type, (iii) SLE definition, (iv) length of SLE
exposure and (v) ascertainment of outcome (supplemen-
tary Table S2, available at Rheumatology online).
The Newcastle-Ottawa scale assesses study quality in
three domains: (i) selection of the study groups, (ii) com-
parability of cohorts on the basis of the design or ana-
lysis and (iii) ascertainment of outcomes of interest
(supplementary Table S3, available at Rheumatology on-
line). Studies were classified as having low, moderate or
high risk of bias based on results from both scales.
The risk of infections in adult patients with systemic lupus erythematosus
https://academic.oup.com/rheumatology 61
Statistical analysis
Meta-analyses were conducted for all outcomes for
which there were at least two studies with low risk of
bias reporting useable data. When two studies reported
findings from overlapping populations, one was selected
based on study quality, population size and length of
study period.
Odds ratios, hazard ratios and rate ratios, prevalence
risk, standardized incidence ratios and standardized
mortality ratios were treated as equal estimates assum-
ing rare occurrence [28] and referred to as RRs through-
out this report. A DerSimonian and Laird [29] random-
effects model was fit to calculate the pooled RR and
95% CIs for all outcomes using the most adjusted RRs.
Heterogeneity was tested using the Cochran’s Q stat-
istic with statistical significance set at P<0.10 and
quantified by the I2 test. Publication bias was assessed
with funnel plots and the Egger’s test [30].
Robustness of results was assessed using the leave1-
out function, which examined the effect of removing in-
dividual studies on pooled estimates [31]. Several
sensitivity analyses were performed, including least
adjusted analysis; only studies published 5 years prior
to 2018; only studies published >5 years prior to 2018;
only studies with low risk of bias; excluding studies only
reporting on non-fatal events; excluding studies only
reporting on non-fatal or fatal events; and excluding
cross-sectional studies. All analyses were conducted in
R version 3.5.1 using the packages metafor and
forestplot.
We describe reported RRs for patient subgroups for
which data were available from specific studies (e.g.
age, disease severity, types of SLE treatment). Due to
the paucity of data, no meta-analyses were conducted
for subgroups except examination for trends.
Results
Literature search
The initial search returned 4187 references after de-
duplication. After title and abstract screening, 111
records were included for full-text review. Nineteen
studies were included in the qualitative synthesis, and
11 studies were included in the quantitative synthesis
(Fig. 1). Sixty-five of 92 studies were excluded because
they did not have an appropriate comparison population
or report a relevant outcome. A list of excluded studies
and the reason for exclusion is outlined in supplemen-
tary Table S4, available at Rheumatology online.
Study characteristics
Nineteen studies were included in the qualitative synthe-
sis [3, 32–49]; the study characteristics are summarized
in Table 1. Fourteen were retrospective cohort studies,
and there was one each of prospective cohort,
single-centre cross-sectional, single-centre retrospective
cohort, single-centre cohort/case–control and
population-based cross-sectional studies. The 19
studies were conducted in Europe (n¼ 7), North
America (n¼ 6), Asia (n¼3), Middle East (n¼ 1), South
America (n¼1) and multiple countries (n¼1; centres in
Europe, North America and Asia). Study periods ranged
between <1 year [40] and 45 years [48]. Studies varied
in outcomes reported: fatal outcomes only (n¼ 6), non-
fatal only (n¼ 1), or both fatal and non-fatal events
(n¼12). The percentage of female patients ranged from
78% [34] to 100% [40]. Average age 6 S.D. (reported in
11 studies) ranged from 34.8 6 14.3 [36] to 63.5 6
18.4 years [47]. A total of 469 570 patients with SLE and
6 528 441 non-SLE/general population/healthy controls
were reported across included studies. Not all studies
reported the number of individuals evaluated. There
were sufficient data for meta-analyses of overall severe
infection, pneumonia, herpes zoster and tuberculosis,
but not for bacteraemia, septicaemia and sepsis out-
comes. No studies reported data on upper respiratory,
gastrointestinal or CNS infections. All infection outcomes
were defined by ICD codes, except four studies [3, 39,
40, 43] that did not describe how infections were identi-
fied (supplementary Table S5, available at
Rheumatology online).
The overall risk of bias per study is shown in Table 1,
and risk of bias assessments are summarized in supple-
mentary Table S6, available at Rheumatology online.
Seventeen studies were determined as having low risk
of bias; one study (a population-based cross-sectional
study) [39] had moderate risk of bias, and one (a single-
centre cross-sectional study) had high risk of bias [40].
Risk of infections in SLE
Eleven studies were included in the meta-analysis
(Table 1). Eight studies were not used: three due to
being stratified according to age [38, 44, 46], three due
to being the only study to report that particular outcome
[35, 39, 40], one stratified by treatment [37] and one
stratified by study period [48].
Forest plots displaying risk of overall severe infection,
pneumonia, herpes zoster and tuberculosis are shown in
Fig. 2A–D. The findings suggest that SLE is associated
with statistically significant increased risk of infections.
For overall severe infection, RRs for each study ranged
from 1.10 to 5.00, and pooled RR was 2.96 (95% CI
1.28, 6.83) (Fig. 2A). For pneumonia, RRs for each study
ranged from 1.50 to 5.10, with a pooled RR of 2.58
(95% CI 1.80, 3.70) (Fig. 2B). For herpes zoster, individ-
ual study RRs ranged from 2.45 to 2.50, with a pooled
RR of 2.50 (95% CI 2.36, 2.65) (Fig. 2C). For tubercu-
losis, RRs for each study ranged from 4.60 to 9.40, and
pooled RR was 6.11 (95% CI 3.61, 10.33) (Fig. 2D).
Sensitivity analysis and heterogeneity
The leave1out method and sensitivity analyses con-
firmed the robustness of the results (Table 2 and sup-
plementary Table S7, available at Rheumatology online).
For overall severe infection, the removal of either
Bjornadal et al. (2004) [34] or Thomas et al. (2014) [47]
resulted in the formerly statistically significant increase
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in RR to become non-statistically significant. The re-
moval of Rees et al. (2016) [3] resulted in an increase in
RR from 2.96 (95% CI 1.28, 6.83) to 4.08 (95% CI 1.28,
6.83). For pneumonia, the leave1out analysis resulted in
very little change in both significance and RR.
For the sensitivity analysis, for overall severe infection,
limiting the studies to those published 5 years prior to
2018 reduced the main analysis RR from 2.96 (95% CI
1.26, 6.83) to 1.80 (95% CI 0.68, 4.74); conversely, limit-
ing the studies to those published >5 years from 2018
increased the RR to 4.98 (95% CI 3.89, 6.37). Similarly,
by limiting the studies to those only reporting fatal over-
all severe infection, RR increased to 4.08 (95% CI 2.75,
6.04). There was little impact on the significance level
for pneumonia, tuberculosis and herpes zoster after
altering any variables described (Table 2).
FIG. 1 Flow diagram of the systematic literature review process

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































I2 test results indicated heterogeneity was high in all
meta-analyses, with the exception of herpes zoster (I2
test 0.0%, P¼ 0.90), ranged from 89.30 to 98.50% and
was statistically significant by the Cochran’s Q statistic.
Visual examination of funnel plots and Egger’s test iden-
tified possible publication bias in all main analyses, ex-
cept for herpes zoster. However, owing to the small
number of studies included in each meta-analysis
and the low power of the test, this may be due to
chance [50].
Qualitative assessment of subgroups
Age
Five studies investigated the association of age with risk
of infection in patients with SLE compared with the gen-
eral population (supplementary Fig. S1, available at
Rheumatology online) [36, 38, 39, 44, 47]. Infections
assessed were hepatitis C [39], herpes zoster [36],
‘other’ infections (excluding pneumonia) [47], overall se-
vere infection [38], pneumococcal disease [44] and
pneumonia [47]. There was large variation in the age
categories presented between studies, and no meta-
analysis was carried out.
The comparative risk of infection (compared with the
general population) was higher for the younger age
groups, and risk of infection in older age groups was
more comparable to the general population. This is par-
ticularly true in the herpes zoster infection study, with
patients aged 18–24 years having higher risk than age-
matched non-SLE controls [RR 8.78 (95% CI 3.08,
24.97)] and lower risk than older age groups [aged
>65 years; RR 2.33 (95% CI 0.79, 6.87)] [36].
This pattern is similar in other studies reporting on
pneumococcal disease [44]. There was no association
between age and the risk of hepatitis C infection [39] or
other infections [47] and overall severe infections [38,
47] in patients with SLE compared with the general
population.
Sex
The association between sex and risk of infection in
patients with SLE was investigated in three studies [36,
39, 47]. The percentages of female participants were
77% [47], 82% [39] and 90% [36]. When stratified by
sex, there was no statistically significant difference in
the RR of infection compared with sex-matched controls
between female and male participants for herpes zoster
[36], hepatitis C [39], overall severe infection, other
infections or pneumonia [47].
SLE treatment
One study observed that patients with SLE had a 6- to
7-fold greater risk of serious infection than the general
population [37]. Within the group of patients with SLE,
this study also assessed effects of starting medications
(antimalarials and glucocorticoids) on the risk of devel-
oping a serious infection. In comparison with patients
with SLE starting antimalarials without glucocorticoids,
the hazard ratio for the risk of serious infection was 3.9
(95% CI 1.7–9.2) for those starting glucocorticoids
15 mg/day without antimalarials- [37].
Time from SLE diagnosis
One study assessed the effect of time from first hospital ad-
mission for an SLE diagnosis on the risk of developing tu-
berculosis compared with the general population [42]. There
was no difference between patients 1year after first SLE
admission [RR 9.1 (95% CI 7.0, 11.7)] and 5years after
first SLE admission [RR 9.1 (95% CI 6.3, 12.9)] [42].
Temporal trends of infections in SLE
One study evaluated age, sex, causes of death (includ-
ing pneumonia, septicaemia and tuberculosis) and the
observed/expected death ratio of patients with SLE
1985–1989 compared with 2003–2007 [45]. For SLE as
an underlying cause, the main non-underlying causes of
death were renal failure, circulatory system diseases,
pneumonia and septicaemia. Over the period, the pro-
portional mention of infectious causes and circulatory
system diseases increased, whereas renal diseases
decreased. The overall observed/expected death ratio
was >1 for tuberculosis, septicaemia and pneumonia,
with no statistically significant difference between both
periods [45].
Discussion
Our findings suggest a 2- to 6-fold increase in relative
risk of infection events in adult patients with SLE com-
pared with the general population or healthy controls.
To our knowledge, this is the first systematic literature
review and meta-analysis conducted to assess risk of
infection in patients with SLE. Multiple sensitivity analy-
ses confirmed the robustness of the results even in the
presence of heterogeneity.
Infections are common in patients with SLE and are
associated with high morbidity and mortality [5, 9]. This
susceptibility may result partly from immunosuppressive
treatment [51] and aberrations in the immune system
associated with SLE, predisposing patients to infection
[52]. Our results further demonstrate this predisposition.
The effects of glucocorticoids and immunosuppres-
sive treatment on risk of infection in patients with SLE
have been extensively described in observational stud-
ies [6, 10, 53–56]. Rúa-Figueroa et al. [10] report signifi-
cant association between any use of glucocorticoids
10 mg/day or immunosuppressors and a shorter time
to severe infection. Increased disease activity has been
associated with dysfunction of the immune system in
patients with SLE, which increases risk of infection in
comparison with patients with inactive SLE [6, 53].
Furthermore, a recent meta-analysis of clinical trial data
demonstrated that high-dose glucocorticoid therapy was
associated with a high risk of serious infections in
patients with LN [57]. In the qualitative part of our study
evaluating risk of infection in patients with SLE and the
effect of general and SLE-related factors on that risk,
we found limited evidence that included disease activity
or glucocorticoid use.
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Nevertheless, in keeping with what is known about
pathophysiology of infection in patients with SLE, the
medical management of these patients should aim to
achieve disease remission by using glucocorticoids at
the lowest effective dosage and for the shortest possible
time period. Consideration should also be given to
reducing infection risk through different strategies such
as general hygienic measures, vaccinations, detection of
latent infections and antibiotic prophylaxis. Such
approaches may include pneumococcal and influenza
vaccinations in patients with stable disease [58, 59],
screening for specific chronic viral infections or for
tuberculosis before glucocorticoids and immunosup-
pressive treatment [60], or the use of appropriate
FIG. 2 Forrest plots: meta-analyses of risk of overall severe infection, pneumonia, herpes zoster and tuberculosis in
SLE
RE: random effects.
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prophylaxes (e.g. oral trimethoprim–sulfamethoxazole for
prophylaxis of Pneumocystis jiroveci pneumonia) or drug
modifications when indicated [60]. Additionally, there is
increasing evidence on the potential role of antimalarial
therapy in the protection against infections in patients
with SLE [37, 61]. Smoking, on the other hand, has
been associated with reduced effectiveness of antima-
larials and shorter time to first severe infection [10, 62].
In our study, we did not find any significant differen-
ces between sex and risk of infection. It is noteworthy
that there are not many studies addressing this topic.
Data in the literature on the association between sex,
clinical presentation and SLE outcomes are limited. The
LUpus in MInorities, NAture versus nurture (LUMINA)
Study Group described poor long-term prognosis
among male patients with SLE compared with female
patients, driven by their accelerated development of
organ damage, particularly in early stages of the disease
[63]. However, in the LUMINA study, there were no
reports of an association between infection and organ
damage or worse clinical outcomes. Although not spe-
cifically focused on infection, a review by Murphy and
Isenberg [64] reported some clinical differences between
male and female patients with SLE, but limited evidence
to support a negative prognostic association between
male gender and disease activity or mortality. Overall,
the results of our research about infections in SLE are in
line with the absence of significant differences in other
clinical features of the disease.
The sensitivity analysis demonstrated a higher risk of
overall severe infection in earlier studies compared with
later studies (studies published >5 years prior to 2018
[33, 34] compared with studies published 5 years prior
to 2018 [3, 47]). This difference may be attributable to
changes in clinical practice during the time periods
assessed, with the earlier studies including patient
cohorts between 1958 and 2001 [33] and 1964 and 1994
[34], and the later studies between 1999 and 2012 [3] and
2000 and 2009 [47]. For pneumonia, studies published
5 years prior to 2018 show an increased risk compared
with studies published >5 years prior. In the recent era,
there have been more effective recognition and strategies
to treat and limit infectious complications. An evaluation
of SLE hospitalizations within the US National Inpatient
Sample from 2000 to 2011 demonstrated increasing
trends in the annual adjusted infections per hospitalization
for pneumonia, bacteraemia, opportunistic fungal, vari-
cella zoster and cytomegalovirus infections; however, in-
fection rates for pneumocystis pneumonia (PCP) declined
during this period [41]. The increasing trend of infections
may be due to increasing use of immunosuppressive
treatment and immune dysregulation from SLE [51, 52].
The observed decline in PCP may also reflect trends
in clinical practice, such as use of prophylaxis or
increasing use of MMF in preference to CYC [41, 65].
Although MMF has shown antimicrobial properties
against PCP in renal transplantation trials and animal
studies [66–68], such data in patients with SLE are lim-
ited. Findings from the Taiwan single-payer National
Health Insurance Research Database from 1997 to 2013
showed increased odds of PCP infections with MMF,
CYC and glucocorticoid use [69]. This study also identi-
fied that use of HCQ reduced the odds of PCP infec-
tions in patients with SLE.
Taken together, the evidence suggests modifiable infec-
tion risk factors and warrants increased research, including
seeking to understand the role of disease activity, treat-
ment and comorbidities. Well-designed trials and observa-
tional studies are needed to support the management and
prevention of infection in patients with SLE, including iden-
tification of patients at high risk of infection and those who
would benefit from vaccination, or patient monitoring to
mitigate risk. Segura et al. [70] developed the SLE Severe
Infection Score, an algorithm for predicting the risk of se-
vere infection in patients with SLE. This tool is useful to
monitor infection risk factors more closely in a weighted
way and could contribute to the establishment of better
strategies for the prevention, early diagnosis and treat-
ment of severe infections in patients with SLE, with the
goal of reducing morbidity and improving survival [70].
The findings from this current work fill an important evi-
dence gap in understanding the risk posed to patients
with SLE and have important strengths. They are general-
izable to different SLE populations because we included
populations from different age and sex groups, and geo-
graphic locations. This review was conducted to the high-
est standards, according to international guidelines on
the conduct and reporting of systematic reviews and
meta-analyses, including the Cochrane Handbook
and Preferred Reporting Items for Systematic Reviews
and Meta-Analyses statements [15, 71, 72].
Some limitations should be considered in interpreting
our findings, primarily the limited number of studies that
met the criteria to be included in both the meta-analysis
and descriptive subgroup analyses. Few studies, in some
instances no studies, were available to enable evaluation
of age, sex, treatment regimen, disease severity and tem-
poral trends of infections in patients with SLE. These limi-
tations emphasize the need for more research.
Conclusion
Infection risk among patients with SLE increases 2- to 6-
fold for overall severe infection, tuberculosis, pneumonia
and herpes zoster compared with the general population
or healthy controls. Demographics and SLE-related fac-
tors, including age, sex, the disease itself and treatment,
are likely to be important in explaining this elevated risk.
This should lead to strengthening the strategies aimed at
prevention of infections in these patients, such as coun-
selling on preventative measures, vaccinations, use of
HCQ, or reduction of the dosage and duration of gluco-
corticoids and immunosuppressants.
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